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Inhaled corticosteroids are considered by many to be 
the most effective therapy available for adults and chil- 
dren with asthma. Recently, it has been recognized 
that inflammation is present in patients with mild asth- 
ma, and US and UK guidelines now recommend that 
therapy with inhaled corticosteroids is initiated at a 
much earlier stage (1,2). In addition, the new guide- 
lines emphasize the need to gain early control of asth- 
ma. This may now mean starting with a higher dose of 
inhaled or oral corticosteroid and then stepping down 
the treatment dosage, rather than gradually increasing 
the dosage until control is achieved. Hence, inhaled 
corticosteroids are being prescribed to more patients, 
at larger doses and for longer periods of time than ever 
before. However, despite their proven efficacy in the 
treatment of asthma, the increase in the frequency of 
use of high-dose corticosteroid therapy has resulted in 
concern about possible systemic adverse events. 
Beclomethasone dipropionate (BDP) was the first 
inhaled corticosteroid introduced into the market- 
place. Its introduction in 1972 represented a significant 
therapeutic advance as its low oral bioavailability, high 
systemic clearance and inhalation formulation impart- 
ed a much wider therapeutic ratio than any oral corti- 
costeroid. Since then, other inhaled corticosteroids 
have been developed and licensed for clinical use. 
Budesonide was introduced in the UK in 1983. 
Currently, budesonide and BDP are the most widely 
prescribed inhaled corticosteroids in the countries 
where they are available, and high-dose formulations 
of these drugs have constituted the most rapidly grow- 
ing segment of inhaled corticosteroid prescriptions 
(3). Although BDP and budesonide differ in potency 
(systemic and topical), glucocorticoid receptor affini- 
ty, systemic bioavailability, clearance and systemic 
half-life, both drugs effectively reduce inflammation of 
the airways (4,5). 
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Over the years there have been many studies evalu- 
ating all aspects of BDP and budesonide, and some of 
these have directly compared the two drugs. Recently 
there have been suggestions that budesonide may offer 
advantages over BDP, in terms of both efficacy and 
safety, in the treatment of asthma. The aim of this 
supplement is to clarify the evidence and to attempt to 
determine, from an objective scientific perspective, 
whether there is any difference between the two treat- 
ments. Hence, this supplement represents an overview 
of the scientific literature that has evaluated the effica- 
cy and systemic activity of both inhaled BDP and 
budesonide. The separate sections, in turn, focus on 
the pharmacokinetics, efficacy, effects on adrenal 
function (including skin thinning and cataracts), 
effects on bone density and metabolism, and effects on 
growth in children of the two inhaled corticosteroids; 
also, each section focuses on studies in which a direct 
comparison of the two drugs has been undertaken. 
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